Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 7, Issue 6, Pages 593-597Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2007.09.008
Keywords
-
Categories
Funding
- Medical Research Council [G0300195] Funding Source: Medline
- Medical Research Council [G0300195] Funding Source: researchfish
- MRC [G0300195] Funding Source: UKRI
Ask authors/readers for more resources
Increased sensitivity of visceral nociceptive pathways contributes to symptoms in an array of clinical gastrointestinal conditions, however, the search for a consistently effective pharmacological agent to treat these conditions remain elusive. Modulation of visceral nociceptive pathways can occur at peripheral, spinal and supra-spinal sites and a dizzying array of potential drug targets exists. Till date, only tricyclic anti-depressants (TCAs) such as amitriptyline and, more recently, selective serotonin reuptake inhibitors (SSRIs) such as citalopram have demonstrated convincing visceral anti-nociceptive properties and clinical benefit in a limited population of patients with visceral hypersensitivity. Unfortunately, there is an incomplete understanding of the receptors and/or primary site of action at which these compounds exert their effects and significant side effects are often encountered. There is a continuing and concerted effort underway to develop target-specific visceral analgesic/anti-hyperalgesic compounds and the aim of this article is to provide a concise update on the most recent advances in this area.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available